Question

A client with an exacerbation of chronic obstructive pulmonary disease has been on oral glucocorticoids and is currently being weaned to triamcinolone (Azmacort) by inhalation. The nurse determines that the client understands the potential adverse effects to watch for during this medication change when the client states the need to report which signs and symptoms?

1) Chills, fever, and generalized rash
2) Vomiting, diarrhea, and increased thirst
3) Blurred vision, headache, and insomnia
4) Anorexia, nausea, weakness, and fatigue

Answer 1

The client needs to watch for symptoms of exacerbation of chronic obstructive pulmonary disease and signs of airway, eye, and skin irritation as potential adverse effects when weaning to triamcinolone (Azmacort).

Step-by-step explanation:

When weaning from oral glucocorticoids to triamcinolone (Azmacort) by inhalation, the client needs to watch for certain signs and symptoms and report them promptly. One such symptom is the development of an exacerbation of chronic obstructive pulmonary disease. Other symptoms to watch for include airway irritation, eye and skin irritation, dyspnea, cough, sore throat, chest tightness, wheezing, and bronchospasm. These symptoms can indicate adverse effects of the medication change and should be reported to the healthcare provider for further evaluation and management.